Adverse Effects of Blood Transfusion

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/114

encourage image

There's no tags or description

Looks like no tags are added yet.

115 Terms

1
New cards

Transfusion Reaction Definition

Any transfusion-related adverse event occurring during or after transfusion of whole blood, components, or plasma products.

2
New cards

Major Categories of Transfusion Reactions

Acute vs. delayed, immune vs. non-immune, and infectious vs. non-infectious reactions.

3
New cards

Initial Step in Transfusion Reaction Recognition

Involves the patient, the transfusionist, and the physician responsible for the patient at the time of transfusion.

4
New cards

Intermediate and Final Steps in Transfusion Reaction Evaluation

Involves the Transfusion Service technical staff and the Transfusion Service physician.

5
New cards

Immediate First Step When Investigating a Potential Reaction

Stop the transfusion.

6
New cards

Fever Criterion for a Transfusion Reaction

Fever of 39°C or higher, or a rise of 2°C or more.

7
New cards

Hypoxemia Criterion for a Transfusion Reaction

Oxygen saturation below 90%.

8
New cards

Tachycardia Criteria for a Transfusion Reaction

Heart rate above 120/min or a rise of greater than 40/min.

9
New cards

Tachypnea Criterion for a Transfusion Reaction

Respiratory rate greater than 28/min.

10
New cards

Blood Pressure Criteria for a Transfusion Reaction

Hypertension (rise in BP >30 mmHg) or Hypotension (drop in BP >30 mmHg).

11
New cards

Pain Symptoms in Transfusion Reactions

Abdominal, back, chest, infusion site pain, and headache.

12
New cards

Renal Signs of Transfusion Reactions

Hematuria, hemoglobinuria, and oliguria or anuria.

13
New cards

Cutaneous Manifestations of Transfusion Reactions

Urticaria, pruritus, and rash.

14
New cards

AABB Clerical Check Requirements

Check the component bag, label, paperwork, and pretransfusion patient specimen.

15
New cards

AABB Laboratory Testing Requirements

Repeat ABO testing on post-transfusion sample and perform a direct antiglobulin test (DAT).

16
New cards

AABB Visual Specimen Check

Visual check of pre- and post-transfusion specimens for hemolysis.

17
New cards

AABB Component Quarantine Requirement

Quarantine additional components prepared from the same donor collection.

18
New cards

AABB Reporting Requirement

Report findings to the transfusion service supervisor or medical director.

19
New cards

Key Respiratory Transfusion Reactions to Compare

Transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO), and transfusion-associated dyspnea.

20
New cards

Transfusion-Transmitted Bacterial Infection Comparison

Compare clinical manifestations and microbiology between contaminated RBC versus platelet products.

21
New cards

AHTR Immune Mechanism

Recipient IgM or IgG antibodies recognize donor red cell antigens, forming immune complexes and activating complement.

22
New cards

AHTR Laboratory Evaluation Findings

Positive DAT, decreased haptoglobin, elevated bilirubin and LDH, hemoglobinemia, and hemoglobinuria.

23
New cards

DHTR Timeline and Cause

Presents 24 hours to 28 days post-transfusion due to an amnestic or primary immune response.

24
New cards

TRALI Pathogenesis Pathways

Immune TRALI via leukocyte antibodies and non-immune TRALI via a two-hit patient predisposition model.

25
New cards

TRALI Radiographic Finding

Classic bilateral 'white-out' appearance of non-cardiogenic pulmonary edema.

26
New cards

TACO Pathophysiology

Cardiovascular system workload is exceeded, manifesting as congestive heart failure and fluid overload.

27
New cards

TACO At-Risk Populations

Pediatric patients, patients with severe anemia, and CHF patients.

28
New cards

Hypotensive Transfusion Reaction Cause

Potentially caused by increased bradykinin levels in stored blood products.

29
New cards

FNHTR Primary Prevention

Leukoreduction of blood products.

30
New cards

Allergic Transfusion Reaction Prophylaxis

Antihistamines or corticosteroids given prior to or during transfusion for patients with a reaction history.

31
New cards

TA-GVHD Mechanism

Transfused viable donor T-lymphocytes mount an immunologic attack against recipient host tissues.

32
New cards

TA-GVHD Prevention Method

Gamma irradiation of blood units.

33
New cards

Post-Transfusion Purpura (PTP) Treatment

Intravenous immunoglobulin (IVIg) or plasma exchange for unresponsive cases.

34
New cards

Iron Overload Management

Chelation therapy to address multi-organ damage from excessive iron accumulation.

35
New cards

Common Platelet TTBI Pathogens

Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus lugdunensis.

36
New cards

Common RBC TTBI Pathogens

Enterobacter cloacae, E. coli, Klebsiella species, Pseudomonas aeruginosa, and Serratia marcescens.

37
New cards

Silent Transfusion-Related Adverse Events

Incidents like sample collection errors, overdosing/underdosing, and red cell or platelet alloimmunization.

38
New cards

Transfusion Reactions Presenting With Fever

AHTR, FNHTR, TAS, TRALI, DHTR, and TA-GVHD.

39
New cards

Transfusion Reactions Presenting Without Fever

DSHTR, PTP, Iron Overload, Allergic, Hypotensive, TAD, TACO, and Acute Pain.

40
New cards

Definition of HDFN

Destruction of fetal or neonatal red blood cells by antibodies produced by the pregnant individual.

41
New cards

Primary Cause of HDFN

About 95% of cases are caused by maternal antibodies directed against the Rh antigen D (anti-D).

42
New cards

IgG Subclasses in HDFN

IgG1 and IgG3 are the most efficient subclasses in causing RBC hemolysis and crossing the placenta.

43
New cards

Rh HDFN Firstborn Phenomenon

An Rh-positive firstborn infant of an Rh-negative parent is usually unaffected because the parent has not yet been immunized.

44
New cards

Fetomaternal Hemorrhage Timing

Transplacental hemorrhage occurs in up to 7% of pregnancies during gestation and over 50% at delivery.

45
New cards

Clinically Significant Non-Rh Antibody

Anti-Kell is considered the most clinically significant non-Rh antibody in its ability to cause HDFN due to its presence on immature erythroid cells.

46
New cards

Erythroblastosis Fetalis

Condition where immature fetal RBCs (erythroblasts) are released into circulation due to accelerated bone marrow production responding to hemolysis.

47
New cards

Hydrops Fetalis

Severe anemia and hypoproteinemia leading to high-output cardiac failure with generalized edema, effusions, and ascites.

48
New cards

Bilirubin Processing in Fetus vs Newborn

Indirect bilirubin from fetal RBC destruction is conjugated in the maternal liver; after birth, the immature newborn liver cannot adequately process unconjugated bilirubin.

49
New cards

ABO HDFN Characteristics

Nearly always limited to A or B infants of group O individuals, can occur in the first pregnancy, and is generally milder than Rh HDFN.

50
New cards

Protective Effect of ABO Incompatibility

Major ABO incompatibility between mother and fetus can protect against Rh immunization by destroying fetal cells before the D antigen is recognized.

51
New cards

Prenatal Antibody Screening Timing

Recommended obstetric practice is to perform type and antibody screen at the first prenatal visit, preferably in the first trimester.

52
New cards

Antibody Titration Significance

A difference of greater than 2 dilutions or a titer score change of 10 or more is considered clinically significant.

53
New cards

Paternal Genotyping Purpose

If the pregnant individual has anti-D and the father is D-positive, zygosity testing helps determine if the father is homozygous or heterozygous for the D antigen.

54
New cards

Fetal DNA Testing Window

Amniocentesis or chorionic villous sampling can be performed as early as 10 to 12 weeks' gestation to determine fetal blood group genes.

55
New cards

Rh Immune Globulin (RhIg) Impact

The incidence of HDFN caused by anti-D has steadily decreased since 1968 due to the introduction of RhIg.

56
New cards

Antibody Titer Threshold for MCA-PSV

A titer reproducibly at 32 or above indicates a need for Color Doppler MCA-PSV studies after 16 weeks' gestation.

57
New cards

MCA-PSV Monitoring for Titers Below 32

Repeated at 4-week intervals from 16-20 weeks, then every 2 to 4 weeks in the third trimester.

58
New cards

Amniocentesis in HDFN Management

Uncommonly used because MCA-PSV is noninvasive; measures bilirubin pigment via Delta OD 450 nm.

59
New cards

Intrauterine Transfusion Triggers

Fetal Hb less than 10 g/dL, high Delta OD 450 nm, MCA-PSV indicating anemia, or fetal hydrops on ultrasound.

60
New cards

Intrauterine Transfusion Procedure

Performed by accessing the fetal umbilical vein and injecting donor RBCs directly into the vein.

61
New cards

Cord Blood Testing Challenges for Newborns

ABO antigens and isoagglutinins are not fully developed, causing weak reactions and missing reverse testing.

62
New cards

Blocked Rh Phenomenon in Cord Blood

Can cause false-negative Rh typing and positive Direct Antiglobulin Tests (DAT) due to heavy antibody coating.

63
New cards

Phototherapy Wavelength and Action

Uses 460 to 490 nm light to convert unconjugated bilirubin into less lipophilic, less toxic isomers.

64
New cards

Primary Purpose of Exchange Transfusion

Primarily used to remove high levels of unconjugated bilirubin, maternal antibodies, and sensitized RBCs.

65
New cards

Newborn Transfusion Thresholds

Hemoglobin levels below 10 g/dL may require transfusion, while levels below 7 g/dL indicate severe anemia and hypoxia.

66
New cards

Blood Selection Criteria for HDFN Transfusions

Group O RBCs, antigen-negative for maternal antibodies, CMV-negative, irradiated, and Hgb S negative.

67
New cards

Intravenous Immune Globulin (IVIG) Mechanism

Competes with maternal antibodies for Fc receptors on macrophages in the infant's spleen, reducing hemolysis.

68
New cards

Mechanism of RhIG Prevention

RhIG binds to fetal Rh-positive cells in maternal circulation, leading to their removal by macrophages in the maternal spleen.

69
New cards

Antenatal RhIg Administration Timing

Given early in the third trimester (around 28 weeks) due to the risk of immunization during pregnancy.

70
New cards

Postpartum RhIg Timing

Rh-negative nonimmunized patients should receive RhIG within 72 hours after delivery of an Rh-positive infant.

71
New cards

Fetal-Maternal Hemorrhage Rosette Screen Principle

Maternal RBCs are incubated with anti-D, washed, and mixed with D-positive indicator cells that form rosettes around coated cells.

72
New cards

Kleihauer-Betke Test Purpose

Recommended following a positive screen to quantify the amount of fetal bleed and determine the exact RhIG dosage.

73
New cards

RhIG Regular-Dose Vial Capacity

Contains sufficient anti-D to protect against 15 mL of packed RBCs or 30 mL of whole blood.

74
New cards

Kleihauer-Betke Dosage Calculation Formula

Number of Rh vials equals the Volume of Fetal Bleed divided by 30 mL.

75
New cards

Management of Weak D Individuals

Treated as Rh-negative and given RhIG if genetic testing is unavailable, due to the risk of mosaic D producing anti-D.

76
New cards

Autoantibody Definition

Antibodies directed against an individual's own red blood cells.

77
New cards

AIHA Categories

Alloimmune, Autoimmune hemolytic anemia (AIHA), and Drug-induced immune hemolytic anemia (DIIHA).

78
New cards

Immune Regulatory Failure in Autoantibodies

Loss of suppressor T-cell function preventing excessive B-cell proliferation and antibody overproduction.

79
New cards

Compensated vs Uncompensated AIHA

In compensated anemia, RBC production nearly equals destruction; in uncompensated anemia, destruction exceeds production.

80
New cards

Diagnostic Tests for AIHA

Direct antiglobulin test (DAT) and characterization of autoantibody in serum or eluate using standard identification.

81
New cards

AIHA Thermal Reactivity Distribution

Warm reactive accounts for ~70%, cold reactive for ~18%, and drug-induced for ~12% of reported cases.

82
New cards

Benign Cold Agglutinins

Low titer (

83
New cards

Cold Agglutinins Interference in Testing

Can cause false-positive ABO typing, positive DAT with polyspecific AHG, and interference at the AHG phase.

84
New cards

Anti-I vs Anti-i Specificity

Anti-I reacts strongly with adult cells and weakly with cord cells; anti-i reacts strongly with cord cells and weakly with adult cells.

85
New cards

Anti-H and Anti-IH in Cold Agglutinins

Found in group A1 and A1B sera; react best with group O and A2 cells which have the largest amounts of H antigen.

86
New cards

Pathologic Cold Autoagglutinins

Characterized by reactivity >30°C, typical titer >1000, strong albumin enhancement, and stronger DAT reactions due to C3.

87
New cards

Cold Hemagglutinin Disease (CHD) Association

Chronic or acute cold AIHA often associated with Mycoplasma pneumoniae pneumonia or Infectious Mononucleosis.

88
New cards

Cold Hemagglutinin Disease Immunoglobulin Type

Usually an IgM immunoglobulin that efficiently activates complement.

89
New cards

CHD Clinical Picture and Symptoms

Acrocyanosis, numbness in extremities, and hemoglobinuria exacerbated by cold exposure.

90
New cards

Paroxysmal Cold Hemoglobinuria (PCH)

Least common AIHA, often seen in children after viral illnesses, characterized by episodic hemoglobinuria upon cold exposure.

91
New cards

Donath-Landsteiner Antibody

A biphasic autohemolysin with anti-P specificity that binds at low temperatures and causes complement-mediated intravascular lysis at 37°C.

92
New cards

Donath-Landsteiner Test Procedure

Subjects serum/plasma to 4°C followed by 37°C incubations to confirm the presence of the biphasic hemolysin via hemolysis.

93
New cards

Drug-Induced Immune Hemolytic Anemia (DIIHA) Definition

Immune destruction of RBCs, white blood cells, or platelets caused by therapeutic drugs.

94
New cards

DIIHA Blood Bank Presentation

Typically identified by diagnostic testing requests for suspected hemolytic anemia or unexpected positive DAT results.

95
New cards

Unifying Hypothesis Mechanisms in DIIHA

Includes drug binding to RBC membrane, drug-antibody complexing (innocent bystander), and drug-induced autoantibody formation.

96
New cards

Drug-Adsorption (Hapten) Mechanism

Drugs bind firmly to RBC membrane proteins, with penicillin being the drug most commonly associated.

97
New cards

Penicillin-Induced DIIHA Characteristics

Penicillin antibodies causing positive DAT are most often IgG; patient serum is non-reactive with reagent RBCs.

98
New cards

Drugs Causing Positive DAT via Drug-Adsorption

Penicillin, cephalosporins, and cefotetan.

99
New cards

Drug-Dependent or Immune Complex Mechanism

Drug interacts non-covalently with membrane proteins to form a 'neoantigen' that binds drug antibodies.

100
New cards

Clinical Features of Immune Complex DIIHA

Frequently presents with acute intravascular hemolysis and renal failure, requiring immediate drug cessation.